Saudi Arabia In Vitro Diagnostics Market: Market Size & Forecast 2026

Saudi Arabia represents the largest standalone IVD market in the Gulf Cooperation Council, with demand sustained by a high burden of non-communicable diseases, particularly diabetes, cardiovascular conditions, and obesity. Government health expenditure, supported by Vision 2030 initiatives, continues to upgrade hospitals, diagnostic laboratories, and primary care networks across the kingdom.

• •Market value of approximately $0.93 billion in 2025
• •Projected CAGR of 4.33% through the forecast period
• •Regulated by the Saudi Food and Drug Authority (SFDA), which enforces strict medical device registration requirements

Saudi Arabia's aging population and rising prevalence of lifestyle-related chronic diseases are expanding the need for routine and advanced diagnostic testing across public and private facilities. The kingdom's healthcare privatization agenda under Vision 2030 has spurred investment in new hospitals, laboratory networks, and digital health infrastructure, all of which increase IVD consumption.

• •Rising diabetes and obesity rates among one of the highest prevalence levels globally
• •Healthcare privatization policies encouraging private hospital and laboratory expansion
• •Government investment in medical city projects and digital health platforms

The market is broadly segmented into clinical chemistry, immunoassays, molecular diagnostics, hematology, microbiology, and point-of-care testing, with clinical chemistry and immunoassays capturing the largest revenue shares due to high-volume routine testing needs. Geographically, demand is concentrated in major urban centers such as Riyadh, Jeddah, and Dammam, though Vision 2030 projects are gradually extending access into secondary and remote regions.

• •Clinical chemistry and immunoassays dominate, followed by molecular diagnostics as a fast-growing segment
• •Riyadh and the Central Province account for the highest concentration of diagnostic laboratories and healthcare facilities
• •Point-of-care and molecular diagnostics are gaining traction with investments in precision medicine

What are the recent trends and outlook?

Molecular diagnostics and point-of-care testing are expected to drive the fastest growth, fueled by the kingdom's emphasis on infectious disease surveillance and rapid diagnostic capabilities. Digital integration of laboratory information management systems (LIMS) and AI-assisted diagnostic tools are also shaping procurement priorities, as healthcare providers align with Vision 2030's smart-health objectives.

• •Molecular diagnostics growth supported by investments in genomic research and infectious disease preparedness
• •Increasing adoption of point-of-care testing for decentralized and primary care settings
• •Growing emphasis on local manufacturing partnerships and technology transfer under Saudi industrialization initiatives